Aegle’s capital raise will fund the first clinical trial in the U.S. using exosomes isolated from allogeneic mesenchymal stem cells as therapy. Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal ...
Read More »Aegle Therapeutics receives IND clearance from FDA for stem cell-derived extracellular vesicle therapy
Aegle Therapeutics Corporation, a regenerative medicine company isolating extracellular vesicles (“EVs”) from allogeneic bone marrow derived mesenchymal stem cells (“MSCs”) to treat severe...
Read More »